Conversely, if a TNF antagonist is considered essential in IBD treatment, switching to another agent within the same class might be considered in isolated cutaneous LCV, with close follow-up conditions, to identify the relapse of vasculitis early, as this would render the continued use of an anti-TNF agent prohibitive [23]. The gene discussed is TNF; the disease is inflammatory bowel disease.